KalVista Pharmaceuticals (NASDAQ:KALV) CEO Benjamin Palleiko Sells 3,322 Shares of Stock

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) CEO Benjamin Palleiko sold 3,322 shares of KalVista Pharmaceuticals stock in a transaction that occurred on Tuesday, May 12th. The stock was sold at an average price of $26.71, for a total value of $88,730.62. Following the completion of the transaction, the chief executive officer directly owned 466,375 shares in the company, valued at $12,456,876.25. This trade represents a 0.71% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

KalVista Pharmaceuticals Price Performance

Shares of KalVista Pharmaceuticals stock opened at $26.80 on Thursday. The stock has a market capitalization of $1.37 billion, a P/E ratio of -6.78 and a beta of -0.12. The business’s 50 day simple moving average is $19.97 and its two-hundred day simple moving average is $16.54. The company has a debt-to-equity ratio of 8.18, a current ratio of 7.22 and a quick ratio of 7.21. KalVista Pharmaceuticals, Inc. has a one year low of $9.83 and a one year high of $26.85.

Hedge Funds Weigh In On KalVista Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of KALV. Tudor Investment Corp ET AL purchased a new position in shares of KalVista Pharmaceuticals during the third quarter valued at about $24,360,000. Vestal Point Capital LP increased its position in shares of KalVista Pharmaceuticals by 152.0% during the fourth quarter. Vestal Point Capital LP now owns 1,890,000 shares of the specialty pharmaceutical company’s stock valued at $30,524,000 after buying an additional 1,140,000 shares during the period. Parkman Healthcare Partners LLC increased its position in shares of KalVista Pharmaceuticals by 155.5% during the third quarter. Parkman Healthcare Partners LLC now owns 1,735,003 shares of the specialty pharmaceutical company’s stock valued at $21,132,000 after buying an additional 1,055,940 shares during the period. Ameriprise Financial Inc. increased its position in shares of KalVista Pharmaceuticals by 2,258.6% during the second quarter. Ameriprise Financial Inc. now owns 945,125 shares of the specialty pharmaceutical company’s stock valued at $10,685,000 after buying an additional 905,053 shares during the period. Finally, Elmind Capital LP purchased a new position in shares of KalVista Pharmaceuticals during the fourth quarter valued at about $12,941,000.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on KALV shares. Stifel Nicolaus upped their price objective on shares of KalVista Pharmaceuticals from $39.00 to $42.00 and gave the company a “buy” rating in a research note on Thursday, March 26th. Needham & Company LLC downgraded shares of KalVista Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, April 30th. JonesTrading downgraded shares of KalVista Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Thursday, April 30th. Wall Street Zen downgraded shares of KalVista Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, April 21st. Finally, HC Wainwright downgraded shares of KalVista Pharmaceuticals from a “buy” rating to a “neutral” rating and lowered their price objective for the company from $37.00 to $27.00 in a research note on Friday, May 1st. Three equities research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, KalVista Pharmaceuticals has a consensus rating of “Hold” and a consensus price target of $30.60.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.